Clinical Trials Directory

Trials / Unknown

UnknownNCT05482412

Acute Intense Paraphilic Desire (DSM-V) Down-Regulation Via taVNS Neuro-Modulation [Transcutaneous Afferent Vagus Nerve] With Future Operative Implant Consideration

Acute Paraphilic Pathway Down-Regulation In A Specialized Sensitive Group Using taVNS Modulation

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
American University Of Montserrat · Academic / Other
Sex
Male
Age
21 Years – 60 Years
Healthy volunteers
Accepted

Summary

Transcutaneous Afferent Vagus Nerve Stimulation \[taVNS\] is used to modulate persistent \& intense desire control amongst a specific participant group. Testing Center Order of Deliver Number

Detailed description

taVNS Diagnostic Spectrum Testing Center Order of Delivery 1. \- Addiction - Opioid 2. \- Chronic Pain - Central 3. \- Anxiety + Panic Disorder 4. \- MDD - Major Depression Disorder 5. \- Addiction - Nicotine 6. \- ADHD 7. \- Addiction - Stimulant 8. \- Addiction - Sexual + Love 9. \- Addiction - Paraphilia 10. \- Parkinsons 11. \- Immune Enhancing 12. \- Addiction - Overeating RE-ORDERED CLINICAL TRIAL - NINE Physiologic effects of taVNS stimulation have been extensively researched for over 150 years. Drug-resistant depression (MDD), migraine headaches, pelvic pain modulation, facilitation of motor learning in neonates, post stroke rehabilitation and seizures are some of the conditions investigated with favorable results using taVNS intervention. taVNS physiologic \& mental effects have been noted to have advantageous therapeutic results on a vast diagnostic spectrum. A clinical testing program for pre- and post-test was devised as a means to identify \& measure treatment effects in specific T3, 4 and early 5 (Tanner) sub-group visual stimulation. The programmatic (software) of the stimulation medium created for this study is aimed to abate the use of a phallometric device purposed to measure sexual stimulation effects on participants. Great effort has been assigned for the preservation of visual data to be shared in the investigators' research centre with other researchers internationally. The participant testing platform created for this study allows for a full-proof research ethics anonymous \& confidential registry \& testing process (triple blind). Aggressive optimum (supra-threshold and below-pain threshold) taVNS is the therapeutic modality of choice in order to examine desire down-regulation effects using taVNS. DSM-V stock participants must be sub-grouped in the paraphilic categorical structure of the DSM-V.

Conditions

Interventions

TypeNameDescription
DEVICEtranscutaneous (superficial) afferent electrical nerve stimulation specific for vagus nerveDirect superficial auricular sensory branch of Cr X \[Cranial Nerve Ten Vagus\]

Timeline

Start date
2023-09-15
Primary completion
2024-06-15
Completion
2024-12-15
First posted
2022-08-01
Last updated
2023-07-20

Source: ClinicalTrials.gov record NCT05482412. Inclusion in this directory is not an endorsement.